2021
DOI: 10.1530/eje-21-0596
|View full text |Cite
|
Sign up to set email alerts
|

ENDOCRINOLOGY IN THE TIME OF COVID-19-2021 UPDATES: The management of diabetes insipidus and hyponatraemia

Abstract: COVID-19 has changed the nature of medical consultations, emphasizing virtual patient counseling, with relevance for patients with diabetes insipidus (DI) or hyponatremia. The main complication of desmopressin treatment in DI is dilutional hyponatraemia. Since plasma sodium monitoring is not always possible in times of COVID-19, we recommend to delay the desmopressin dose once a week until aquaresis occurs allowing excess retained water to be excreted. Patients should measure their body weight daily. Patient… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(19 citation statements)
references
References 49 publications
0
19
0
Order By: Relevance
“…Safe in-hospital management of CDI extends beyond timely desmopressin dosing; close monitoring of fluid balance and serum sodium concentration are also key (8,11). Daily measurement of serum sodium and documentation of fluid balance were performed in fewer than half of hospital admissions, these are two further benchmarks that require addressing in future quality improvement projects.…”
Section: Discussionmentioning
confidence: 99%
“…Safe in-hospital management of CDI extends beyond timely desmopressin dosing; close monitoring of fluid balance and serum sodium concentration are also key (8,11). Daily measurement of serum sodium and documentation of fluid balance were performed in fewer than half of hospital admissions, these are two further benchmarks that require addressing in future quality improvement projects.…”
Section: Discussionmentioning
confidence: 99%
“…Specifically, the 2018 Society for Endocrinology guidelines recommend that intravenous or intramuscular administration of desmopressin be used in the setting of excessive and inappropriate urine output for patients with central DI 11 . The 2021 COVID‐19 update to the guidelines further clarifies that that intravenous route should be preferred over other routes of administration based on the potential for reduced absorption 12 …”
Section: What Is Known and Objectivementioning
confidence: 99%
“…11 The 2021 COVID-19 update to the guidelines further clarifies that that intravenous route should be preferred over other routes of administration based on the potential for reduced absorption. 12 Herein we describe how rapidly severe hypernatremia can develop after desmopressin therapy is withheld in patients with central DI as well as parental routes of desmopressin administration when enteral administration is not possible.…”
Section: What Is Known and Objectivementioning
confidence: 99%
“…Absorption of nasal desmopressin may be limited or variable, due to nasal congestion or for other reasons; oral or systemic administration is recommended during COVID-19 infection. [7] Even in the absence of COVID-19 in the patients themselves, many, perhaps most, patients during the pandemic at its height experienced interruptions in care and/or less direct physical interaction with clinical staff as it was replaced by virtual consultations via some form of telemedicine. These changes in care delivery resulted from concerns about patient safety during visits to clinical environments or were necessary due to the re-allocation of staff and resources away from the care of apparently stable medical conditions to look after those with active infection.…”
Section: As With Other Kinds Of Infection Covid-19 Can Complicate The...mentioning
confidence: 99%